Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of dapagliflozin on biochemistry, electrolytes and bioelectrical impedance in type 2 diabetes mellitus
ChiCTR2100052963Phase 4Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: blood biochemistry, urinary electrolytes and 2 more. Started Jan 2022; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100052963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052963.